{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:12:12Z","timestamp":1782868332988,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020638","name":"Allergan Aesthetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020638","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie Company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Masseter muscle prominence (MMP) is a benign condition characterized by a wide, square, or trapezoidal lower facial shape, which may be considered undesirable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate onabotulinumtoxinA (onabotA) efficacy and safety for MMP treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a Phase 2b study, adults with investigator- and participant-assessed bilateral Grade 4\/5 MMP on the 5-grade MMP Scale (MMPS) and MMPS\u2014Participant, respectively, were randomized 1:1:1 to receive a single intramuscular injection of onabotA 48\u2005U, 72\u2005U, or placebo in the masseter muscles. The primary endpoint was the proportion of patients achieving investigator-assessed MMPS Grade \u22643 at Day 90. Adverse events were monitored throughout.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients received onabotA 48\u2005U (n = 53), 72\u2005U (n = 46), or placebo (n = 46). Significantly greater proportions achieved MMPS Grade \u22643 with onabotA vs placebo (90.6%, 91.3%, and 21.7% for onabotA 48\u2005U, 72\u2005U, and placebo, respectively, at Day 90; P &amp;lt; .0001). Improvements in lower facial volume, width, and angle were significantly greater for onabotA vs placebo at all time points. At Day 90, the proportion of patients perceiving improvements was significantly greater with onabotA treatment vs placebo. Significantly more patients were \u201csatisfied\/very satisfied\u201d with onabotA vs placebo through Day 180. Treatment was well tolerated; both onabotA groups had a similar incidence of treatment-emergent adverse events (TEAEs). Nasopharyngitis (onabotA, 3.9% vs placebo, 0%) and upper respiratory infection (2.9% vs 0%, respectively) were the most common TEAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>One injection of onabotA 48 or 72\u2005U was well tolerated and effective in reducing MMP severity as assessed by investigators and patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 1 (Therapeutic)<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjaf042","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:31:59Z","timestamp":1742502719000},"page":"1043-1050","source":"Crossref","is-referenced-by-count":1,"title":["A Controlled Phase 2b Trial to Assess the Efficacy and Safety of a Single Intervention of OnabotulinumtoxinA for Treating Masseter Muscle Prominence"],"prefix":"10.1093","volume":"45","author":[{"given":"Steven","family":"Liew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rivkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Biesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Brandstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beta","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F","family":"Brin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2025091917035223400_sjaf042-B1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/s1808-8694(15)31393-8","article-title":"Benign masseter muscle hypertrophy","volume":"74","author":"Rispoli","year":"2008","journal-title":"Braz J Otorhinolaryngol"},{"key":"2025091917035223400_sjaf042-B2","doi-asserted-by":"publisher","first-page":"39e","DOI":"10.1097\/prs.0000000000005083","article-title":"The masseter muscle and its role in facial contouring, aging, and quality of life: a literature review","volume":"143","author":"Almukhtar","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"2025091917035223400_sjaf042-B3","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1016\/j.jval.2018.04.1015","article-title":"Simultaneous development of patient-reported outcome measures for masseter muscle hypertrophy in an Asia population","volume":"21","author":"Crawford","year":"2018","journal-title":"Value Health"},{"key":"2025091917035223400_sjaf042-B4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.asj.2008.03.003","article-title":"Nonsurgical reshaping of the lower face","volume":"28","author":"Liew","year":"2008","journal-title":"Aesthet Surg J"},{"key":"2025091917035223400_sjaf042-B5","article-title":"Management of masseter hypertrophy and bruxism with Botulinum toxin A","volume":"8","author":"Dalmedo","year":"2021","journal-title":"PMFA J"},{"key":"2025091917035223400_sjaf042-B6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.fsc.2009.11.014","article-title":"Botox facial slimming\/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width","volume":"18","author":"Wu","year":"2010","journal-title":"Facial Plast Surg Clin North Am"},{"key":"2025091917035223400_sjaf042-B7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/archfaci.6.3.188","article-title":"Botulinum toxin for masseter reduction in Asian patients","volume":"6","author":"Ahn","year":"2004","journal-title":"Arch Facial Plast Surg"},{"key":"2025091917035223400_sjaf042-B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0266-4356(94)90169-4","article-title":"Botulinum toxin treatment of bilateral masseteric hypertrophy","volume":"32","author":"Smyth","year":"1994","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2025091917035223400_sjaf042-B9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1046\/j.1524-4725.2003.29117.x","article-title":"Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement","volume":"29","author":"Kim","year":"2003","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/0266-4356(94)90168-6","article-title":"The medical management of masseteric hypertrophy with botulinum toxin type A","volume":"32","author":"Moore","year":"1994","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2025091917035223400_sjaf042-B11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1524-4725.2003.29116.x","article-title":"Botulinum toxin type A treatment for contouring of the lower face","volume":"29","author":"Park","year":"2003","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00006534-200102000-00004","article-title":"Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment","volume":"107","author":"von Lindern","year":"2001","journal-title":"Plast Reconstr Surg"},{"key":"2025091917035223400_sjaf042-B13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2024.10.064","article-title":"Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: primary results from a randomized phase 2 study","volume":"92","author":"Carruthers","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2025091917035223400_sjaf042-B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2025091917035223400_sjaf042-B15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/01.prs.0000239453.67423.99","article-title":"Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle","volume":"119","author":"Kim","year":"2007","journal-title":"Plast Reconstr Surg"},{"key":"2025091917035223400_sjaf042-B16","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/jocd.14858","article-title":"Efficacy of botulinum toxin in masseter muscle hypertrophy for lower face contouring","volume":"21","author":"Kundu","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"2025091917035223400_sjaf042-B17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/01.prs.0000153236.79775.a0","article-title":"The use of botulinum toxin type A in aesthetic mandibular contouring","volume":"115","author":"Kim","year":"2005","journal-title":"Plast Reconstr Surg"},{"key":"2025091917035223400_sjaf042-B18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00266-007-0081-8","article-title":"Botulinum toxin a for lower facial contouring: a prospective study","volume":"31","author":"Yu","year":"2007","journal-title":"Aesthetic Plast Surg"},{"key":"2025091917035223400_sjaf042-B19","first-page":"39","article-title":"Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines","volume":"10","author":"Beer","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"2025091917035223400_sjaf042-B20","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1177\/1090820X12474629","article-title":"A review of onabotulinumtoxinA (Botox)","volume":"33","author":"Lorenc","year":"2013","journal-title":"Aesthet Surg J"},{"key":"2025091917035223400_sjaf042-B21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2025091917035223400_sjaf042-B22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","article-title":"Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines","volume":"44","author":"De Boulle","year":"2018","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B23","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1097\/DSS.0000000000001414","article-title":"Forehead line treatment with onabotulinumtoxinA in subjects with forehead and glabellar facial rhytids: a phase 3 study","volume":"43 Suppl 3","author":"Fagien","year":"2017","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B25"},{"key":"2025091917035223400_sjaf042-B26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/DSS.0000000000000357","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines","volume":"41","author":"Carruthers","year":"2015","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"2025091917035223400_sjaf042-B28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B29","author":"US Food and Drug Administration"},{"key":"2025091917035223400_sjaf042-B30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/dss.0000000000000223","article-title":"The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy","volume":"40","author":"Bae","year":"2014","journal-title":"Dermatol Surg"},{"key":"2025091917035223400_sjaf042-B31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jocd.12721","article-title":"Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy","volume":"17","author":"Yeh","year":"2018","journal-title":"J Cosmet Dermatol"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjaf042\/62492337\/sjaf042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/10\/1043\/62492337\/sjaf042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/10\/1043\/62492337\/sjaf042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:04:00Z","timestamp":1758315840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/45\/10\/1043\/8088127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjaf042","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,3,20]]}}}